Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome

Fei Li Kuang,Fanny Legrand,Michelle Makiya,JeanAnne Ware,Lauren Wetzler,Thomas Brown,Tamika Magee,Brent Piligian,Pryscilla Yoon,Jamie H. Ellis,Xiaoping Sun,Sandhya R. Panch,Astin Powers,Hawwa Alao,Sheila Kumar,Martha Quezado,Li Yan,Nancy Raitano Lee,Roland Kolbeck,Paul Newbold,Mitchell H. Goldman,Michael P. Fay,Paneez Khoury,Irina Maric,Amy D. Klion

Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome

2019

Abstract Background Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a monoclonal ...

Keywords:

Medicine
Diabetes mellitus
Surgery
Dermatology
Hypereosinophilic syndrome
PDGFRA
Benralizumab
Biopsy
Antibody
Monoclonal
Eosinophilia
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations